The US Food and Drug Administration (FDA) has expanded the emergency use authorisation (EUA) for the Pfizer-BioNTech COVID-19 vaccine (Comirnaty®) to include adolescents 12 through 15 years of age. This was done as an amendment to the EUA, originally issued in December 2020 which allowed its administration in individuals 16 years of age and older.
“The FDA’s expansion of the emergency use authorisation for the Pfizer-BioNTech COVID-19 vaccine to include adolescents 12 through 15 years of age is a significant step in the fight against the COVID-19 pandemic,” stated Acting FDA Commissioner, Dr Janet Woodcock.
